1149 related articles for article (PubMed ID: 28223168)
1. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
2. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
3. Survival-associated alternative splicing signatures in non-small cell lung cancer.
Zhao D; Zhang C; Jiang M; Wang Y; Liang Y; Wang L; Qin K; Rehman FU; Zhang X
Aging (Albany NY); 2020 Apr; 12(7):5878-5893. PubMed ID: 32282333
[TBL] [Abstract][Full Text] [Related]
4. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
Gao X; Wu Y; Yu W; Li H
Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
[TBL] [Abstract][Full Text] [Related]
5. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
[TBL] [Abstract][Full Text] [Related]
6. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
7. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
8. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
11. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.
Sun F; Yang X; Jin Y; Chen L; Wang L; Shi M; Zhan C; Shi Y; Wang Q
Mol Med Rep; 2017 Jul; 16(1):609-616. PubMed ID: 28560415
[TBL] [Abstract][Full Text] [Related]
13. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
14. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
[TBL] [Abstract][Full Text] [Related]
15.
Zhang W; Li T; Hu B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
[TBL] [Abstract][Full Text] [Related]
16. Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma.
Jiang L; Zhu W; Streicher K; Morehouse C; Brohawn P; Ge X; Dong Z; Yin X; Zhu G; Gu Y; Ranade K; Higgs BW; Yao Y; Huang J
BMC Cancer; 2014 Feb; 14():131. PubMed ID: 24571613
[TBL] [Abstract][Full Text] [Related]
17. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
18. Identification of 17 mRNAs and a miRNA as an integrated prognostic signature for lung squamous cell carcinoma.
Zhang J; Bing Z; Yan P; Tian J; Shi X; Wang Y; Yang K
J Gene Med; 2019 Aug; 21(8):e3105. PubMed ID: 31215090
[TBL] [Abstract][Full Text] [Related]
19. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
Liu B; Chen Y; Yang J
Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
[TBL] [Abstract][Full Text] [Related]
20. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
